The increased expression of SRSF3 enhances gemcitabine resistance of pancreatic cancer cells both in vitro and in vivo, whereas silence of SRSF3 by siRNAs exhibits an opposite effect. Here, SRSF3 is linked to pancreatic neoplasm.